title: ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT.
abstract: We present a 77-year-old woman with no histor of trauma, or associated with low-energy trauma, admitted to our clinic after three weeks of a left femoral fracture threated in Orthopedic Clinic. The patient was in treatment with bisphosphonates over 10 years for osteoporosis.
  
  
  CONCLUSIONS
  The causal re lationship between prolonged bisphosphonate use and the occurrence of atypical femora fractures (AFF) has not yet been established. For the patient at high risk of fracture, it may be beneficial to continue bisphosphonate treatment beyond five years. The absolute risk of atypical femoral fractures is low (about 100 cases per 100,000 person-years among long term users). For most people with osteoporosis, the proven fragility-fracture risk-reduction. benefits of bisphosphonates outweigh the risks of AFF.
authors.forename: Corina
authors.initials: C
authors.lastname: Găleşanu
authors.forename: Veronica
authors.initials: V
authors.lastname: Mocanu
authors.forename: C
authors.initials: C
authors.lastname: Buzdugă
authors.forename: A
authors.initials: A
authors.lastname: Florescu
authors.forename: V
authors.initials: V
authors.lastname: Zaharia
authors.forename: V
authors.initials: V
authors.lastname: Lisnic
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005264:Femoral Fractures / Q000139:chemically induced*; D005598:Fractures, Spontaneous / Q000139:chemically induced*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates